doi:10.1016/j.bmcl.2006.05.003
Copyright © 2006 Elsevier Ltd All rights reserved.
Identification of metabolites of the tryptase inhibitor CRA-9249: Observation of a metabolite derived from an unexpected hydroxylation pathway
References and further reading may be available for this article. To view references and further reading you must
purchase this article.
Walter Yua, Jeffrey M. Denerc,
,
, Daniel A. Dickmanc, Paul Grothausb, Yun Linga, Liang Liua, Chris Havela, Kimberly Maleskyb, Tania Mahajanb, Colin O’Brianc, Emma J. Sheltonb, David Sperandiob, Zhiwei Tongb, Robert Yeeb and Joyce J. Mordentia
aDepartment of Drug Metabolism and Pharmacokinetics, Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080, USA
bDepartment of Medicinal Chemistry, Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080, USA
cDepartment of Process Chemistry, Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080, USA
Received 24 February 2006;
revised 28 April 2006;
accepted 1 May 2006.
Available online 18 May 2006.
Abstract
The metabolites of the tryptase inhibitor CRA-9249 were identified after exposure to liver microsomes. CRA-9249 was found to be degraded rapidly in liver microsomes from rabbit, dog, cynomolgus monkey, and human, and less rapidly in microsomes from rat. The key metabolites included cleavage of an aryl ether, in addition to an unexpected hydroxylation of the amide side chain adjacent to the amide nitrogen. The chemical structures of both metabolites were confirmed by synthesis and comparison to material isolated from the liver microsomes. Several suspected hydroxylated metabolites were also synthesized and analyzed as part of the structure identification process.
Keywords: Metabolism; Metabolite identification; Synthesis; Active metabolite
Scheme 1. Metabolism of the tryptase inhibitor CRA-9249 (1). Reagents and conditions: (a) 20 μM CRA-9249, liver microsomes (1.5 mg protein/mL) from five species, 2 mM NAPDH, 10 mM MgCl2, 37 °C, up to 3 h.
Scheme 2. Reagents and conditions: (a) PyBroP, 2-aminoethanol (500 mole %), DMF then crystallization, 31%.
Scheme 3. Reagents and conditions: (a) Et3N, THF, RT to −20 °C then AcCl, <20 °C, 90%; (b) 25% AcOH in H2SO4 then HNO3/H2SO4/AcOH (4:1:1), 50%; (c) aq NaOH, 85 °C to reflux; (d) H2, 10% Pd–C, EtOH, 48% from 11; (e) PyBroP, N-methylmorpholine (NMM), DMF, −10 °C; (f) PyBrOP, DMF, −10 °C, then 13, NMM. −10 °C; (g) AcOH, 85 °C, 9% from 15.
Scheme 4. Reagents and conditions: (a) aq NaOH, DMPU, 120 °C, 86%; (b), H2, 10% Pd–C, EtOH; (c) 19, EtOH, reflux, 43% from 17; (d) 15, DMPU, 185 °C, 73%; (e) (PhSO2)2N–F, EtOH, reflux, 3%.
Scheme 5. Proposed pathway for the formation and degradation of the α-hydroxyamide metabolite 23. (a) 20 μM CRA-9249, liver microsomes (1.5 mg protein/mL) from five species, 2 mM NAPDH, 10 mM MgCl2, 37 °C, up to 3 h; (b) DMSO–water,
1 month.
Scheme 6. Metabolites of glyburide (25).
Scheme 7. Reagents and conditions: (a) 1 M t-BuOK in THF, DMSO; (b) BrCH2CH(OCH3)2; (c) H2SO4 (cat), acetone–water (10:1), 33% from 28; (d) 22, CH3CN, 90 °C, 3% after preparative HPLC.
Table 1.
In vitro inhibition of mast cell tryptase by compound 1 and synthetic samples of proposed metabolites


Corresponding author. Tel.: +1 650 866 6695; fax: +1 650 866 6655.